Scarica l'app Stockscreener
6.50
4.17%
0.26
Pre-mercato:
6.47
-0.03
-0.46%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Verastem Inc Borsa (VSTM) Ultime notizie
Breakout Zone: What is the Moat Score of Verastem IncJuly 2025 Market Mood & Safe Capital Growth Tips - baoquankhu1.vn
Microvast, Datavault AI, RH, Becton Dickinson, Verastem Shake-Up - TipRanks
Retail Trends: Does Verastem Inc have a competitive edgeJuly 2025 Levels & Risk Controlled Swing Alerts - baoquankhu1.vn
Have Verastem Insiders Been Selling Stock? - simplywall.st
CEO Change: Is Icahn Enterprises LP showing insider buyingJuly 2025 Chart Watch & Accurate Buy Signal Notifications - baoquankhu1.vn
Resistance Check: Does Verastem Inc outperform in volatile markets2025 Market Outlook & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Insider Sell: Dan Paterson Sells Shares of Verastem Inc (VSTM) - GuruFocus
Daniel Calkins Sells 5,039 Shares of Verastem (NASDAQ:VSTM) Stock - MarketBeat
Insider Selling: Verastem (NASDAQ:VSTM) CEO Sells 10,321 Shares of Stock - MarketBeat
EPS Watch: Why Verastem Inc stock is trending among retail tradersTrade Risk Assessment & Reliable Entry Point Alerts - Bộ Nội Vụ
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Chartmill
Polar Capital Holdings Plc Increases Stake in Verastem Inc - GuruFocus
Verastem, Inc. (VSTM) Investor Outlook: Biotech Stock With Over 100% Potential Upside - directorstalkinterviews.com
Can Verastem Inc. stock continue upward trendJuly 2025 Price Swings & Consistent Income Trade Recommendations - Улправда
Is Verastem Inc. stock attractive after correctionMarket Performance Recap & Verified Short-Term Trading Plans - ulpravda.ru
Will Verastem Inc. stock attract more institutional investorsJuly 2025 Outlook & Safe Entry Point Identification - Улправда
Verastem updates oncology strategy in new corporate presentation - TipRanks
RBC Raises Price Target on Verastem to $15 From $14, Keeps Outperform, Speculative Risk - marketscreener.com
Immuneering plummets following phase 2 data of atebimetinib for pancreatic cancer - Seeking Alpha
Verastem (NASDAQ:VSTM) Shares Up 19.3%Should You Buy? - MarketBeat
Verastem shifts focus to KRAS G12D and pancreatic programs - MSN
Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects - MSN
What's Going On With Verastem Stock Friday?Verastem (NASDAQ:VSTM) - Benzinga
Verastem ends trial of Avmapki Fakzynja combo with Amgen's Lumakras in NSCLC - MSN
Verastem Oncology stock drops after hours after discontinuing a clinical trial in lung cancer - MSN
Verastem stock steady as Mizuho reiterates Outperform rating By Investing.com - Investing.com Canada
Verastem Shifts Focus to KRAS G12D and Pancreatic Programs - TipRanks
Verastem to discontinue Avmapki/Fakzynja combo in KRAS G12C-mutated NSCLC - The Pharma Letter
Verastem (VSTM) Halts Development of Avutometinib/Defactinib Com - GuruFocus
Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC (VSTM) - Seeking Alpha
Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch - ts2.tech
Verastem (NASDAQ:VSTM) Shares Cross Above 200 Day Moving AverageShould You Sell? - MarketBeat
Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Verastem Oncology (VSTM) Shifts Focus to Promising KRAS G12D Inh - GuruFocus
Calkins, Verastem CFO, sells $628 in shares By Investing.com - Investing.com South Africa
Verastem Oncology provides update on Ramp 203 phase 1/2 clinical trial - marketscreener.com
Verastem Oncology Stock Drops After Hours After Discontinuing A Clinical Trial In Lung Cancer - Stocktwits
Verastem to Discontinue RAMP 203 Clinical Trial in Lung Cancer After Interim Data Read - marketscreener.com
Verastem stock falls after discontinuing KRAS G12C lung cancer trial By Investing.com - Investing.com Nigeria
Verastem (VSTM) Shifts Focus to Promising KRAS G12D Inhibitor in Cancer Treatment - GuruFocus
Verastem stock falls after discontinuing KRAS G12C lung cancer trial - Investing.com
Verastem discontinues KRAS G12C lung cancer trial to focus on G12D - Investing.com Canada
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer - Business Wire
Calkins, Verastem CFO, sells $628 in shares - Investing.com India
Behavioral Patterns of VSTM and Institutional Flows - Stock Traders Daily
Verastem, Inc.'s (NASDAQ:VSTM) Stock Retreats 26% But Revenues Haven't Escaped The Attention Of Investors - 富途牛牛
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):